Engineering Yeast for Producing Human Glycoproteins: Where Are We Now?

Overview

Journal Future Microbiol

Specialties Infectious Diseases
Microbiology

Date 2015 Jan 20

PMID 25598335

Citations 16

Authors

Bram Laukens

Charlotte De Visscher

Nico Callewaert

Affiliations

Soon will be listed here.

Abstract

Yeast has advanced as an alternative for mammalian cell culture for the production of recombinant therapeutic glycoproteins. Engineered yeast strains not only allow to mimic the human N-glycosylation pathway but also specific types of human O-glycosylation. This is of great value for therapeutic protein production and indispensable to determine the structure-function relationships of glycans on recombinant proteins. However, as the technology matures, some limitations have come up that may hamper biomedical applications and must be considered to exploit the full potential of the unprecedented glycan homogeneity obtained on relevant biopharmaceuticals. In this special report, we focus on the recent developments in N- and O-glycosylation engineering in yeasts of industrial importance, to produce recombinant therapeutics with customized glycans.

Citing Articles

Novel human recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in a glyco-engineered strain.

Pimentel-Vera L, Rodriguez-Lopez A, Espejo-Mojica A, Ramirez A, Cardona C, Reyes L Heliyon. 2024; 10(12):e32555.

PMID: 38952373 PMC: 11215262. DOI: 10.1016/j.heliyon.2024.e32555.

Yeasts as Biopharmaceutical Production Platforms.

Kulagina N, Besseau S, Godon C, Goldman G, Papon N, Courdavault V Front Fungal Biol. 2023; 2:733492.

PMID: 37744146 PMC: 10512354. DOI: 10.3389/ffunb.2021.733492.

Engineering -glycosylation in modified -linked oligosaccharide (ManGlcNAc∼ManGlcNAc) strains.

Li S, Sun P, Gong X, Chang S, Li E, Xu Y RSC Adv. 2022; 9(15):8246-8252.

PMID: 35518704 PMC: 9061240. DOI: 10.1039/c8ra08121b.

Successive remodeling of IgG glycans using a solid-phase enzymatic platform.

Hsu Y, Verma D, Sun S, McGregor C, Mangion I, Mann B Commun Biol. 2022; 5(1):328.

PMID: 35393560 PMC: 8990068. DOI: 10.1038/s42003-022-03257-4.

Strategies to control therapeutic antibody glycosylation during bioprocessing: Synthesis and separation.

Edwards E, Livanos M, Krueger A, Dell A, Haslam S, Smales C Biotechnol Bioeng. 2022; 119(6):1343-1358.

PMID: 35182428 PMC: 9310845. DOI: 10.1002/bit.28066.

References

Akeboshi H, Kasahara Y, Tsuji D, Itoh K, Sakuraba H, Chiba Y . Production of human beta-hexosaminidase A with highly phosphorylated N-glycans by the overexpression of the Ogataea minuta MNN4 gene. Glycobiology. 2009; 19(9):1002-9. DOI: 10.1093/glycob/cwp080. View

Liu L, Gomathinayagam S, Hamuro L, Prueksaritanont T, Wang W, Stadheim T . The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in Glycoengineered Pichia Pastoris. Pharm Res. 2012; 30(3):803-12. DOI: 10.1007/s11095-012-0921-3. View

Chiba Y, Sakuraba H, Kotani M, Kase R, Kobayashi K, Takeuchi M . Production in yeast of alpha-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease. Glycobiology. 2002; 12(12):821-8. DOI: 10.1093/glycob/cwf096. View

Hamilton S, Davidson R, Sethuraman N, Nett J, Jiang Y, Rios S . Humanization of yeast to produce complex terminally sialylated glycoproteins. Science. 2006; 313(5792):1441-3. DOI: 10.1126/science.1130256. View

Ohashi T, Fujiyama K, Takegawa K . Identification of novel α1,3-galactosyltransferase and elimination of α-galactose-containing glycans by disruption of multiple α-galactosyltransferase genes in Schizosaccharomyces pombe. J Biol Chem. 2012; 287(46):38866-75. PMC: 3493928. DOI: 10.1074/jbc.M112.347351. View

Verostek M, Atkinson P, Trimble R . Structure of Saccharomyces cerevisiae alg3, sec18 mutant oligosaccharides. J Biol Chem. 1991; 266(9):5547-51. View

Wang C, Chen J, Tseng Y, Hsu C, Hung Y, Chen S . Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci U S A. 2009; 106(43):18137-42. PMC: 2775302. DOI: 10.1073/pnas.0909696106. View

Han Y, Kanbe T, CHERNIAK R, Cutler J . Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect Immun. 1997; 65(10):4100-7. PMC: 175590. DOI: 10.1128/iai.65.10.4100-4107.1997. View

Beck A, Reichert J . Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs. 2012; 4(4):419-25. PMC: 3499336. DOI: 10.4161/mabs.20996. View

10.

Nett J, Cook W, Chen M, Davidson R, Bobrowicz P, Kett W . Characterization of the Pichia pastoris protein-O-mannosyltransferase gene family. PLoS One. 2013; 8(7):e68325. PMC: 3698189. DOI: 10.1371/journal.pone.0068325. View

11.

Nakayama K, Maeda Y, Jigami Y . Interaction of GDP-4-keto-6-deoxymannose-3,5-epimerase-4-reductase with GDP-mannose-4,6-dehydratase stabilizes the enzyme activity for formation of GDP-fucose from GDP-mannose. Glycobiology. 2003; 13(10):673-80. DOI: 10.1093/glycob/cwg099. View

12.

Parsaie Nasab F, Aebi M, Bernhard G, Frey A . A combined system for engineering glycosylation efficiency and glycan structure in Saccharomyces cerevisiae. Appl Environ Microbiol. 2012; 79(3):997-1007. PMC: 3568548. DOI: 10.1128/AEM.02817-12. View

13.

Oh D, Park J, Kim M, Cheon S, Kim E, Moon H . Glycoengineering of the methylotrophic yeast Hansenula polymorpha for the production of glycoproteins with trimannosyl core N-glycan by blocking core oligosaccharide assembly. Biotechnol J. 2008; 3(5):659-68. DOI: 10.1002/biot.200700252. View

14.

Cheon S, Kim H, Oh D, Kwon O, Kang H . Remodeling of the glycosylation pathway in the methylotrophic yeast Hansenula polymorpha to produce human hybrid-type N-glycans. J Microbiol. 2012; 50(2):341-8. DOI: 10.1007/s12275-012-2097-2. View

15.

Luong M, Lam J, Chen J, Levitz S . Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine. 2007; 25(22):4340-4. PMC: 2001175. DOI: 10.1016/j.vaccine.2007.03.027. View

16.

Vella G, Paulsen H, SCHACHTER H . Control of glycoprotein synthesis. IX. A terminal Man alpha l-3Man beta 1- sequence in the substrate is the minimum requirement for UDP-N-acetyl-D-glucosamine: alpha-D-mannoside (GlcNAc to Man alpha 1-3) beta 2-N-acetylglucosaminyltransferase I. Can J Biochem Cell Biol. 1984; 62(6):409-17. DOI: 10.1139/o84-056. View

17.

Nakayama K, Nagasu T, SHIMMA Y, Kuromitsu J, Jigami Y . OCH1 encodes a novel membrane bound mannosyltransferase: outer chain elongation of asparagine-linked oligosaccharides. EMBO J. 1992; 11(7):2511-9. PMC: 556726. DOI: 10.1002/j.1460-2075.1992.tb05316.x. View

18.

Hossler P . Protein glycosylation control in mammalian cell culture: past precedents and contemporary prospects. Adv Biochem Eng Biotechnol. 2011; 127:187-219. DOI: 10.1007/10_2011_113. View

19.

Dean N . Asparagine-linked glycosylation in the yeast Golgi. Biochim Biophys Acta. 1999; 1426(2):309-22. DOI: 10.1016/s0304-4165(98)00132-9. View

20.

De Pourcq K, Tiels P, Van Hecke A, Geysens S, Vervecken W, Callewaert N . Engineering Yarrowia lipolytica to produce glycoproteins homogeneously modified with the universal Man3GlcNAc2 N-glycan core. PLoS One. 2012; 7(6):e39976. PMC: 3386995. DOI: 10.1371/journal.pone.0039976. View